145 related articles for article (PubMed ID: 15689049)
1. Skeletal benefit after one year of risedronate therapy in patients with rheumatoid arthritis and glucocorticoid-induced osteoporosis: a prospective study.
Lange U; Illgner U; Teichmann J; Schleenbecker H
Int J Clin Pharmacol Res; 2004; 24(2-3):33-8. PubMed ID: 15689049
[TBL] [Abstract][Full Text] [Related]
2. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients.
Eastell R; Devogelaer JP; Peel NF; Chines AA; Bax DE; Sacco-Gibson N; Nagant de Deuxchaisnes C; Russell RG
Osteoporos Int; 2000; 11(4):331-7. PubMed ID: 10928223
[TBL] [Abstract][Full Text] [Related]
3. Comparative studies on effect of risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients.
Yamada S; Takagi H; Tsuchiya H; Nakajima T; Ochiai H; Ichimura A; Iwata H; Toriyama T
Yakugaku Zasshi; 2007 Sep; 127(9):1491-6. PubMed ID: 17827929
[TBL] [Abstract][Full Text] [Related]
4. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
Seibel MJ; Naganathan V; Barton I; Grauer A
J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
[TBL] [Abstract][Full Text] [Related]
5. [Clinical features of fracture with glucocorticoid induced osteoporosis and rheumatoid arthritis].
Nampei A; Hashimoto J
Clin Calcium; 2006 Nov; 16(11):1866-70. PubMed ID: 17079854
[TBL] [Abstract][Full Text] [Related]
6. A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial.
Kushida K; Fukunaga M; Kishimoto H; Shiraki M; Itabashi A; Inoue T; Kaneda K; Morii H; Nawata H; Yamamoto K; Ohashi Y; Orimo H
J Bone Miner Metab; 2004; 22(5):469-78. PubMed ID: 15316868
[TBL] [Abstract][Full Text] [Related]
7. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
Devogelaer JP; Sambrook P; Reid DM; Goemaere S; Ish-Shalom S; Collette J; Su G; Bucci-Rechtweg C; Papanastasiou P; Reginster JY
Rheumatology (Oxford); 2013 Jun; 52(6):1058-69. PubMed ID: 23365149
[TBL] [Abstract][Full Text] [Related]
8. Risedronate: clinical usage.
Chapurlat RD; Delmas PD
Int J Clin Pract; 2001 May; 55(4):275-8. PubMed ID: 11406915
[TBL] [Abstract][Full Text] [Related]
9. Risedronate prevents the loss of microarchitecture in glucocorticoid-induced osteoporosis in rats.
Dalle Carbonare L; Bertoldo F; Valenti MT; Zordan S; Sella S; Fassina A; Turco G; Realdi G; Lo Cascio V; Giannini S
J Endocrinol Invest; 2007 Oct; 30(9):739-46. PubMed ID: 17993765
[TBL] [Abstract][Full Text] [Related]
10. [Randomized controlled trials for the prevention and treatment of glucocorticoid-induced osteoporosis].
Suzuki Y
Clin Calcium; 2006 Nov; 16(11):1834-42. PubMed ID: 17079850
[TBL] [Abstract][Full Text] [Related]
11. Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis.
Ste-Marie LG; Sod E; Johnson T; Chines A
Calcif Tissue Int; 2004 Dec; 75(6):469-76. PubMed ID: 15478000
[TBL] [Abstract][Full Text] [Related]
12. Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.
Bahlous A; Bouzid K; Sahli H; Sallami S; Abdelmoula J
Tunis Med; 2009 Jun; 87(6):380-1. PubMed ID: 19927782
[TBL] [Abstract][Full Text] [Related]
13. Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results.
Morishita M; Nagashima M; Wauke K; Takahashi H; Takenouchi K
J Rheumatol; 2008 Mar; 35(3):407-13. PubMed ID: 18260178
[TBL] [Abstract][Full Text] [Related]
14. [Osteoporosis in the patients with rheumatoid arthritis (3) : the efficacy and the selection of the osteoporosis therapeutic drug].
Nakayama H
Clin Calcium; 2007 Oct; 17(10):1607-12. PubMed ID: 17906416
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the efficacy of etidronate therapy in preventing glucocorticoid-induced bone loss in patients with inflammatory rheumatic diseases. A randomized study.
Cortet B; Hachulla E; Barton I; Bonvoisin B; Roux C
Rev Rhum Engl Ed; 1999 Apr; 66(4):214-9. PubMed ID: 10339777
[TBL] [Abstract][Full Text] [Related]
16. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Ettinger MP
Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
[TBL] [Abstract][Full Text] [Related]
17. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.
Eastell R; Barton I; Hannon RA; Chines A; Garnero P; Delmas PD
J Bone Miner Res; 2003 Jun; 18(6):1051-6. PubMed ID: 12817758
[TBL] [Abstract][Full Text] [Related]
18. Bone Tissue Properties Measurement by Reference Point Indentation in Glucocorticoid-Induced Osteoporosis.
Mellibovsky L; Prieto-Alhambra D; Mellibovsky F; Güerri-Fernández R; Nogués X; Randall C; Hansma PK; Díez-Perez A
J Bone Miner Res; 2015 Sep; 30(9):1651-6. PubMed ID: 25736591
[TBL] [Abstract][Full Text] [Related]
19. Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study.
Muscoso E; Puglisi N; Mamazza C; Lo Giudice F; Testai M; Abbate S; Santangelo A; Panebianco P; Maugeri D
Eur Rev Med Pharmacol Sci; 2004; 8(2):97-102. PubMed ID: 15267123
[TBL] [Abstract][Full Text] [Related]
20. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
